Last updated on April 2019

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)


Brief description of study

Mepolizumab is a humanized monoclonal antibody. In conditions where eosinophilia is considered to play an important part in the pathology, including eosinophilic asthma, HES, and eosinophilic granulomatosis with polyangiitis, a consistent reduction in blood eosinophil counts is observed in association with mepolizumab administration, with concomitant clinical improvement. This is a 32-week treatment period, randomized, double-blind, placebo-controlled, parallel group, multicentre study of mepolizumab in adolescent and adult subjects with severe HES receiving standard of care (SoC) therapy. This study will demonstrate the efficacy of mepolizumab compared with placebo based on maintenance of control of HES symptoms during the treatment period. The study will comprise of a screening period of up to approximately 4 weeks followed by a 32-Week study treatment period (subjects will be randomized 1:1 to placebo or mepolizumab) and up to 8-week additional follow-up period (12 weeks after the last dose of study treatment).

Clinical Study Identifier: NCT02836496

Contact Investigators or Research Sites near you

Start Over

GSK Investigational Site

Rochester, MN United States

GSK Investigational Site

Salt Lake City, UT United States

GSK Investigational Site

Bruxelles, Belgium

GSK Investigational Site

Leuven, Belgium

GSK Investigational Site

Lille Cedex, France

GSK Investigational Site

Nantes Cedex 1, France

GSK Investigational Site

Suresnes, France

GSK Investigational Site

Toulouse Cedex 9, France

GSK Investigational Site

Kirchheim -Teck, Germany

GSK Investigational Site

Mannheim, Germany

GSK Investigational Site

Muenchen, Germany

GSK Investigational Site

Fulda, Germany

GSK Investigational Site

Hannover, Germany

GSK Investigational Site

Guadalajara, Mexico

GSK Investigational Site

Villahermosa, Mexico

GSK Investigational Site

Bucharest, Romania

GSK Investigational Site

Saint-Petersburg, Russian Federation

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Pozuelo (Madrid), Spain

GSK Investigational Site

Salamanca, Spain

GSK Investigational Site

Valencia, Spain

GSK Investigational Site

Leicester, United Kingdom

GSK Investigational Site

Mar del Plata, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Napoli, Italy

GSK Investigational Site

Zapopan, Mexico

GSK Investigational Site

Targu Mures, Romania

GSK Investigational Site

Moscow, Russian Federation

GSK Investigational Site

St Petersburg, Russian Federation

GSK Investigational Site

New Haven, CT United States

GSK Investigational Site

Charleston, SC United States

GSK Investigational Site

Firenze, Italy

GSK Investigational Site

Krakow, Poland

GSK Investigational Site

Monterrey, Mexico

GSK Investigational Site

Cincinnati, OH United States

GSK Investigational Site

San Diego, CA United States

GSK Investigational Site

Ciudad Autonoma de Buenos Aires, Argentina

GSK Investigational Site

Mayfield Heights, OH United States

GSK Investigational Site

Porto Alegre, Brazil

GSK Investigational Site

Sorocaba, Brazil

GSK Investigational Site

La Plata, Argentina

GSK Investigational Site

Maringa, Brazil

GSK Investigational Site

Blumenau, Brazil

GSK Investigational Site

Gdansk, Poland

GSK Investigational Site

Cluj-Napoca, Romania

GSK Investigational Site

Santo André - SP, Brazil

GSK Investigational Site

Málaga, Spain

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.